Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Arcus Biosciences, Inc. RCUS
$18.42
+$0.41 (2.22%)
На 18:00, 12 мая 2023
+128.01%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1327094737.00000000
-
week52high
36.13
-
week52low
15.70
-
Revenue
112000000
-
P/E TTM
-4
-
Beta
0.87266400
-
EPS
-3.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 04 авг 2022 г. |
| Truist Securities | Buy | Buy | 08 июл 2022 г. |
| Goldman Sachs | Neutral | Neutral | 12 мая 2022 г. |
| Goldman Sachs | Neutral | Neutral | 11 мая 2022 г. |
| Citigroup | Buy | Buy | 19 ноя 2021 г. |
| Goldman Sachs | Neutral | Neutral | 02 сент 2022 г. |
| Morgan Stanley | Overweight | 11 окт 2022 г. | |
| SVB Leerink | Outperform | Outperform | 03 ноя 2022 г. |
| Citigroup | Buy | Buy | 23 ноя 2022 г. |
| B of A Securities | Neutral | 18 ноя 2022 г. | |
| Barclays | Overweight | Overweight | 21 дек 2022 г. |
| Citigroup | Buy | Buy | 20 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jarrett Jennifer | D | 414946 | 1600 | 27 янв 2023 г. |
| Jarrett Jennifer | D | 416546 | 300 | 26 янв 2023 г. |
| Jaen Juan C. | A | 185900 | 185900 | 23 янв 2023 г. |
| Jaen Juan C. | A | 324682 | 45800 | 23 янв 2023 г. |
| Jarrett Jennifer | A | 185900 | 185900 | 23 янв 2023 г. |
| Jarrett Jennifer | A | 416846 | 45800 | 23 янв 2023 г. |
| Nuyten Dimitry SA | A | 138200 | 138200 | 23 янв 2023 г. |
| Nuyten Dimitry SA | A | 76500 | 34000 | 23 янв 2023 г. |
| Tang Carolyn C. | A | 138200 | 138200 | 23 янв 2023 г. |
| Tang Carolyn C. | A | 97539 | 34000 | 23 янв 2023 г. |
Новостная лента
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:52
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.96 per share a year ago.
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
28 февр 2023 г. в 18:49
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Buy 3 Top Profitable Stocks Using Net Income Ratio
Zacks Investment Research
14 февр 2023 г. в 08:17
Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio.
Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround
Zacks Investment Research
12 янв 2023 г. в 11:18
The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectations
Proactive Investors
20 дек 2022 г. в 11:51
Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer drug combinations. The results showed the program is viable but left investors questioning how the pair and their proposed therapeutic could compete against other more established companies in the tough research and development space.